Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

OTHER 4INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 477Neoplasms 292Breast Neoplasms 281Colorectal Neoplasms 223Neoplasm Metastasis 188Prostatic Neoplasms 168Ovarian Neoplasms 166Lung Neoplasms 155Multiple Myeloma 153Recurrence 132Melanoma 116Pancreatic Neoplasms 115Squamous Cell Carcinoma of Head and Neck 105Endometrial Neoplasms 99Stomach Neoplasms 98Leukemia, Myeloid, Acute 97Small Cell Lung Carcinoma 84Leukemia, Lymphocytic, Chronic, B-Cell 83Triple Negative Breast Neoplasms 81Lymphoma, Non-Hodgkin 81Carcinoma, Renal Cell 80Carcinoma, Hepatocellular 77Urinary Bladder Neoplasms 76Lymphoma, Large B-Cell, Diffuse 72Lymphoma, Follicular 64Advanced Solid Tumors 64Lymphoma 60Glioblastoma 57Parkinson Disease 4, Autosomal Dominant Lewy Body 56Head and Neck Neoplasms 54

Interventions

Lomustine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Neoplasm Recurrence, Local × 90 days × Clear all
NCT07100730 2026-04-16

IPAX BrIGHT

Telix Pharmaceuticals (Innovations) Pty Limited

Phase 3 Recruiting
50 enrolled
CNS

Brain Neoplasms, Glioblastoma, Neoplasm Recurrence, Local, Neoplasms, Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡